115 related articles for article (PubMed ID: 19625344)
1. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
Gill S; Carney D; Ritchie D; Wolf M; Westerman D; Prince HM; Januszewicz H; Seymour JF
Ann Oncol; 2010 Feb; 21(2):331-334. PubMed ID: 19625344
[TBL] [Abstract][Full Text] [Related]
2. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
[TBL] [Abstract][Full Text] [Related]
3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies.
Szász R; Telek B; Illés Á
Pathol Oncol Res; 2021; 27():1609742. PubMed ID: 34257611
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
Hallek M; Schmitt B; Wilhelm M; Busch R; Kröber A; Fostitsch HP; Sezer O; Herold M; Knauf W; Wendtner CM; Kuse R; Freund M; Franke A; Schriever F; Nerl C; Döhner H; Thiel E; Hiddemann W; Brittinger G; Emmerich B;
Br J Haematol; 2001 Aug; 114(2):342-8. PubMed ID: 11529853
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.
MacCallum S; Groves M; Brass D; Cunningham J; Sales M; Gelly K; Tauro S
J Clin Pathol; 2009 May; 62(5):468-70. PubMed ID: 19398596
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
9. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
Tam CS; Wolf MM; Januszewicz EH; Grigg AP; Prince HM; Westerman D; Seymour JF
Cancer; 2004 Nov; 101(9):2042-9. PubMed ID: 15372472
[TBL] [Abstract][Full Text] [Related]
10. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review.
Cencini E; Fabbri A; Lauria F; Bocchia M
Ann Hematol; 2018 May; 97(5):821-829. PubMed ID: 29340761
[TBL] [Abstract][Full Text] [Related]
12. Magnitude and associated factors of cytopenias among antiretroviral therapy naïve Human Immunodeficiency Virus infected adults in Dessie, Northeast Ethiopia.
Tamir Z; Seid A; Haileslassie H
PLoS One; 2019; 14(2):e0211708. PubMed ID: 30759131
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases.
Shvidel L; Tadmor T; Braester A; Bairey O; Rahimi-Levene N; Herishanu Y; Klepfish A; Shtalrid M; Berrebi A; Polliack A;
Ann Hematol; 2013 May; 92(5):661-7. PubMed ID: 23274356
[TBL] [Abstract][Full Text] [Related]
14. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
15. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
Gill S; Lane SW; Crawford J; Cull G; Joske D; Marlton P; Mollee PN; Prince HM; Seymour JF
Ann Hematol; 2008 Sep; 87(9):727-34. PubMed ID: 18401583
[TBL] [Abstract][Full Text] [Related]
16. The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
Polizzotto MN; Tam CS; Milner A; Januszewicz EH; Prince HM; Westerman D; Wolf MM; Seymour JF
Cancer; 2006 Aug; 107(4):773-80. PubMed ID: 16847886
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
19. Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias.
Mangaonkar AA; Ferrer A; Pinto E Vairo F; Cousin MA; Kuisle RJ; Gangat N; Hogan WJ; Litzow MR; McAllister TM; Klee EW; Lazaridis KN; Stewart AK; Patnaik MM
Mayo Clin Proc; 2019 Sep; 94(9):1753-1768. PubMed ID: 31256854
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
